Richard Hepburn MRCVS has launched what is thought to be the world's first equine gastric ulcer study, designed to improve understanding and knowledge of ulceration in performance horses.
Mr Hepburn is conducting the InnerVision study of performance horses, which is being championed by the University of Liverpool, as part of his PhD.
21 appointed practices across the UK are participating in the study, and with each practice scoping between 10 and 20 animals, it will include well over 200 performance horses. Mr Hepburn said: "Gastric ulceration in sports horses is poorly understood, especially compared with racehorses. But what we do know is that it's a very important factor in the performance and well-being of many horses in training and competition."
2012 Paralympic Gold medallist Deb Criddle MBE also attended the launch event. She explained the difference that regular gastroscopy and ulcer management of Paralympic team horses had made to her success. Speaking about her Beijing ride, Pavaroti, she said: "If it weren't for the diagnosis and treatment of Pavaroti's ulcers I don't know what we'd have done. I would probably have had to withdraw him from training, so it made the difference between our partnership continuing or not".
Mr Hepburn expects a prevalence of approximately 60% and, keen to increase understanding of glandular ulceration, participants are being tasked to scope all areas of the stomach, pylorus and duodenum to ensure that every incidence of ulceration is diagnosed and recorded.
He says he is particularly eager to find out more about glandular disease, which hitherto has had little research: "Glandular disease appears to have a very different aetiology to squamous ulceration, and often presents with different signs. We also believe that prevalence of glandular ulceration is most common in sports horses."
"We hope that publication of this study will help all equine vets in their work with performance horses and the quest to prevent and manage equine ulcers," he added.
Merial is supporting the study with management assistance.
Virbac has launched Inflacam, a meloxicam-based NSAID for the alleviation of pain in both acute and chronic musculo-skeletal disorders in dogs and horses.
Inflacam is presented both as an oral suspension and as a chewable tablet for dogs. The suspension is available in 200ml, 100ml, 42ml and 15ml sizes with a measuring syringe provided. The tablets come in two sizes - 1 mg and 2.5 mg - and are available in packs of 100. It is available for horses as an oral suspension.
Virbac Product Manager Chris Geddes MRCVS, said: "Virbac is well known for launching innovative products in areas such as dermatology and reproduction but we also aim to support practices by offering tried and trusted practice 'standards' for everyday use. Inflacam fits this brief well - meloxicam is the most commonly-used NSAID in dogs and we are delighted to add it to our range."
For more information contact your territory manager or call Virbac on 01359 243 243.
Six individuals have been announced as the winners of the second annual Ceva Animal Welfare Awards, honoured for their contributions to the prevention and reduction of animal welfare problems in the UK and abroad.
All winners were originally nominated by friends, colleagues or family. The judging panel consisted of panel chairman and veterinary surgeon Chris Laurence MBE, Ross Tiffin of the International Cat Care (formerly the Feline Advisory Bureau), Dennis Baker, OBE, Chief Executive at Wood Green, the Animal Charity and media vet, Joe Inglis. Marc Abraham also assisted in the Volunteer categories.
Dr. Pascal Raoul, Ceva's Head of Global Pharmaceuticals, said: "Ceva is delighted to host these Animal Welfare Awards as they help to highlight the incredible affection and care that people have for animals. With 6 billion people living in megacities in the future, companion animals will often be their major link to nature. The benefits that animals have on improving human health are well documented; in turn we all have a duty to protect them and this evening we have seen some of the best examples, from professionals, members of the public, young and old as to how that should be done."
Timothy Phillips, a Plymouth-based vet from the Elm Veterinary Group (above right), was awarded the Chris Laurence Vet of the Year Award for his 15 years of charitable work in the Greek Islands with Friends of the Strays of Greece. Tim performs surgeries and other treatments, helping to establish a re-homing system, with dogs fully vaccinated and declared healthy by the vets before being flown out of Greece.
Veterinary Nurse Scott Parry of Bridge Veterinary Surgery was awarded Welfare Nurse of the Year for his work with the RSPCA's Brent Knoll Animal Centre. Scott has spent hours of his own time raising funds and helping with the rehabilitation of a number of traumatised dogs. He also recently assisted in an RSPCA visit to a travellers' camp to vaccinate more than 50 dogs following an outbreak of Parvo Virus on the site.
Other award winners included Logan McKerron, aged 6, who was awarded Young Person of the Year for his fundraising for Hearing Dogs for Deaf People; Kim Taylor, co-founder of the charity Animal Care Egypt, was awarded the Charity Professional of the Year accolade for her work setting up a large animal hospital helping more than 26,000 animals every year; Faye Stacey of People4Ponies in Devon was awarded the UK Volunteer of the Year Award for the large part she has played in stopping ear cutting, notching and tagging of equines in the UK; Jen White has been named International Volunteer of the Year for her work with the Gambia Horse and Donkey Trust.
Zoetis, formerly Pfizer Animal Health has launched Ovatec Plus, which it claims will make equine faecal collection and in-practice worm count testing quicker and easier.
Ovatec Plus is designed to facilitate the in-house detection of worm burdens by enabling the coproscopic examination of parasite eggs, larvae and cysts. Zoetis says the built-in sample collection scoop allows for hands-off, quick, clean sample collection and controlled sample size, while the built-in cap, which can be written on for easy identification, snaps shut to seals the contents safely for contamination-free transport.
The system is based on zinc sulphate flotation technology, with a flotation time of ten minutes to provide rapid analysis. The Ova-Spin feature will break up difficult samples. The positive-locking filter chamber prevents any spill of test samples and reduces operator exposure to potential hazards. The overflow reservoir prevents overfills leaking onto the lab bench.
Zoetis says the high sensitivity and excellent specificity of Ovatec Plus enable informed treatment decisions to be made. A study has shown that samples proving negative with Ovatec Plus provide 95% certainty that the sample is <150epg and 100% certainty that the sample is <250epg, which means treatment may not be necessary1. Samples that prove positive, with one or more eggs seen, can be verified using a quantitative technique if needed, alternatively treatment may be indicated.
Ben Lacey, equine business unit manager at Zoetis, said: "Ovatec Plus is an excellent addition to our equine worm control portfolio. It's ideal for use in many test situations, giving a quick, easy and convenient solution."
To find out more, speak to your Zoetis Account Manager, call 0845 300 8034 or email CustomerSupportUK@zoetis.com.
Reference
Kruuse has launched a range of seven specialized sterile surgical disposable drapes and gowns developed for the surgery team working in equine clinics or hospitals.
The company says its new surgical sets have been designed so they include a comprehensive set of sterile drapes, towels, instrument covers and adhesive tapes needed to perform particular procedures:
Andrew Groom, Managing Director, Kruuse UK Ltd. said: "This exciting new range of products increase the Kruuse's equine product portfolio and develop further our commitment to provide specialist species available products to support the veterinary practitioner."
Boehringer Ingelheim has announced that its 'Talk About Laminitis' campaign will run from Mid March until the end of June.
Last year, the initiative saw over 9000 horses and ponies tested for PPID through its free ACTH test scheme. This year, to build on this success and support the testing of even more animals, the company has announced a high impact, co-ordinated campaign to drive awareness that up to 90% of laminitis cases may have an underlying endocrine cause1,2.
Once again, Boehringer is urging veterinary surgeons to carry out free ACTH blood tests on laminitic or foot-sore horses as part of the campaign, which is backed by Redwings, The British Horse Society and World Horse Welfare.
Professor Andy Durham from the Liphook Equine Hospital, where the ACTH tests are performed, said: "We are learning so much from these tests. For example, we are now recognising PPID routinely in laminitic horses and ponies as young as 10 years old, and in the spring when we might expect to see more EMS cases, where veterinary surgeons have also tested for PPID we are seeing both abnormally elevated ACTH and insulin. Unless the PPID is addressed, horses will continue to be at risk of painful recurrent laminitic episodes which is a significant welfare issue to the horse and extremely frustrating for owners."
To participate in the scheme, veterinary surgeons and horse owners can download ACTH blood test vouchers from www.talkaboutlaminitis.co.uk. Attach the voucher to the ACTH sample submission form and the ACTH laboratory fees will not be charged.
Lee Hackett from The British Horse Society said: "Without the 'Talk About Laminitis' initiative and the support of Boehringer Ingelheim, literally thousands of horses may not be receiving the appropriate treatment and management for their laminitis to help prevent recurrence. We hope as many veterinary surgeons as possible get involved this year to continue this welfare success."
To ensure that horse owners are fully aware of the initiative, a PR and advertising campaign in the equine consumer media will start in March. The ad campaign includes an infomercial on Horse & Country TV (SKY Channel 280), with viewer numbers in excess of 450,000 per month.
There will also be a live online broadcast for horse owners on endocrinopathic laminitis presented by David Rendle BVSc MVM CertEM(IntMed) DipECEIM MRCVS, from the Liphook Equine Hospital in Hampshire. The one-hour webinar, which takes place at 8.00pm on Wednesday 10 April, will educate horse owners on how the veterinary profession's understanding of this debilitating and devastating disease has been completely revolutionised over the past five years. It will be followed by an interactive Q&A session when viewers will be able to pose questions for David to answer.
David said: "As our knowledge of the two hormonal diseases responsible for the majority of cases of laminitis improves, veterinary surgeons can offer their clients more comprehensive advice on treatment options to prevent laminitis. For many owners who have struggled with this condition, this is an absolute revelation and has enormous welfare benefits".
Horse owners can register to view the online programme by visiting www.talkaboutlaminitis.co.uk.
To ensure that veterinary surgeons are versed in the most up to date research available, Boehringer Ingelheim will also be hosting a webinar for veterinary professionals at 8.00pm on Wednesday 13th March, presented by Professor Andy Durham BSc BVSc CertEP DEIM DipECEIM MRCVS. The online seminar, 'The laminitis revolution.... An update on our understanding of endocrinopathic causes of laminitis', will entitle the viewer to a downloadable certificate for one hour of CPD. To register, visit www.bi-academy.co.uk. Places are limited, so register early to avoid disappointment. The webinar will also be available to view after the event on demand.
For further information on how you can promote 'Talk About Laminitis' in your practice contact your Boehringer Ingelheim Territory Manager or call 01344 746959
References
1. Karikoski et al. (2011). The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital. Domestic Animal Endocrinology 41 111-117
2. Donaldson et al. (2004). Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc;224:1123-1127.
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
The Animal Health Trust's (AHT) Dr Sue Dyson has been awarded a place in the International Equine Veterinarians Hall of Fame, in recognition of her contribution to hoof care in horses.
Sue, who is Head of Clinical Orthopaedics at the AHT, has lectured internationally and is known for both her clinical work with horses and an extensive research record, having published more than 200 refereed papers on lameness and diagnostic imaging in scientific journals. She has also co-authored several veterinary textbooks as well as training and competing as a high-level rider in international events.
Established in 1997, the International Equine Veterinarians Hall of Fame honours veterinary surgeons who have contributed to the knowledge and recognition of proper hoof care for horses. Vets are nominated either as practicing equine vets who work closely with farriers in the field, or as college and industry vets involved in teaching, research or other important aspects of equine veterinary and hoof care.
Anyone can nominate an equine vet for the award, which is sponsored by the American Farriers Journal, but selection is completed by previous inductees into the International Equine Veterinarians Hall of Fame. Awards are presented each year during the International Hoof-Care Summit in Cincinnati, Ohio.
Sue said: "I was completely surprised, but absolutely thrilled, to learn that I had been selected to join the distinguished list of people who have previously been appointed to the International Equine Veterinarians Hall of Fame.
"I think it is very humbling to recognise that, despite the knowledge that my team and I have amassed in the last 30 years, there is so much more to learn. From every new finding come many more questions. I hope that the enthusiastic dedication of my team will continue to result in learning and discovering more, and inspire others to do likewise, to the ultimate benefit of the welfare of our great friend, the horse."
Sue has has worked at the AHT for 30 years and is currently researching the association between hindlimb lameness and saddle slip. She has observed some association between the two for several years, however saddle slip has traditionally been attributed to an ill-fitting saddle, asymmetry of the horse's back shape or a crooked rider.
In 2011 Sue carried out a prospective research project with Intern Line Greve: 'Saddle slip may be an indicator of the presence of hindlimb lameness'. It was presented at the 51st Annual Congress of the British Equine Veterinary Association, Birmingham 2012, and identified that in some cases, saddle slip was directly linked to the presence of hindlimb lameness.
Research results showed that of 128 horses assessed for lameness grade and degree of saddle slip when ridden by two riders, the saddle consistently slipped to one side in 54% of the horses with hindlimb lameness, in comparison to just 4% of the horses with forelimb lameness. Diagnostic analgesia to abolish the hindlimb lameness eliminated the saddle slip in 97% of the horses observed in the study.
Sue and Line are currently undertaking further research to measure movement of the back, and forces under the saddle, with the aim of explaining biomechanically what is happening during the occurrence of saddle slip.
Defra Minister David Heath has announced the latest bute (phenylbutazone) test results. The presence of bute has been confirmed in 8 samples out of 206 tests.
Chief Medical Officer Professor Dame Sally Davies has stated that horsemeat containing phenylbutazone presents a very low risk to human health.
Responding to these latest developments the British Veterinary Association (BVA) and British Equine Veterinary Association (BEVA) have issued the following statement:
"The presence of phenylbutazone (or bute) in horses intended for the food chain will be of concern to consumers who rightly expect the UK food chain to be robust. We are grateful to the Chief Medical Officer for clarifying the very low level of risk that this presents to human health and we will work with the FSA and Defra in any way we can to assist their investigations into these incidents.
"The ability to treat horses with bute is very important for equine welfare. Bute provides affordable, long-term pain relief for horses and is unique in this respect.
"The UK Horse Passport Regulations are designed to facilitate the ongoing medical treatment of horses not intended for the human food chain, whilst ensuring that these animals do not enter the food chain.
"We fully support the concept of the Horse Passport Regulations but have argued for some time that there are problems with the system in terms of the number of Passport Issuing Authorities and the vulnerability of the system to fraud. We are very keen to continue our dialogue with Defra and others to find ways to make the system more robust.
"Our members are aware of the strict rules regarding the regulation of medicines (including bute) and the use of horse passports, and in recent years we have provided clear guidance on the regulations to help both vets and their clients. These incidents will hopefully reinforce these messages amongst horse owners and all of us involved in equine healthcare."
Guidance notes are available via the BEVA website Medicines Page (http://www.beva.org.uk/useful-info/Vets/Guidance/Medicines)
The British Equine Veterinary Association (BEVA) has launched two guides to help veterinary professionals and their clients negotiate the complexities of equine insurance.
BEVA highlights that with up to 40% of horses becoming ill or injured in any one year and 25% of insured horses having a claim in any one year, vet fees insurance is a sensible way for horse owners to budget for unexpected healthcare costs.
The Veterinary Surgeon's guide to riding and sport horse insurance provides general guidelines to help vets understand the requirements and issues relating to equine insurance. It explains the three main types of insurance cover available: veterinary fees, death and permanent loss of use, as well as insurance recommendations for pre-purchase and pre-insurance vetting. The final section contains a jargon-busting guide to commonly used insurance terminology.
Complementing the vet guide is The BEVA leisure and sports horse Insurance Guide for horse owners, a handout for clients about to embark on taking out insurance. It covers the frequently asked questions relating to vets fees and death, including when and how to insure, the importance of pre-purchase vetting, exclusions and permanent loss of use.
Andrew Harrison, Junior Vice President of BEVA, said: "Whether a vet or a horse owner, understanding equine insurance can be intimidating for the best of us. The new guides should make it easier for you and your clients to understand the finer points of policies, premiums and claim protocols."
The guides can be downloaded from the BEVA website via the following links:
For additional information visit www.beva.org.uk
The Department for Environment, Food and Rural Affairs (Defra) and the Food Standards Agency (FSA) are reminding veterinary surgeons of their legal responsibilities under the Horse Passport Regulations 2009.
The move follows a small number of horses testing positively for the presence of phenylbutazone, which, if consumed, can be harmful to human health.
Defra and the FSA have asked for the assistance of the profession in ensuring that treatment with phenylbutazone is properly recorded in Horse Passports and have said that they are working together to understand the cause of the positive tests, and what longer term measures can be put in place to stop this happening.
In the interim, all horses slaughtered for human consumption will be sampled for the presence of phenylbutazone, with immediate effect.
The letter from Defra and the FSA can be downloaded from the RCVS website.
The full advice can be read in a Veterinary Medicines Directorate/Defra leaflet, which can be found online at http://www.vmd.defra.gov.uk/pdf/leaflet_horses.pdf.
Mark Bowen, Chair of the British Equine Veterinary Association's Health and Medicines Committee, said: "The number of horses entering the human food chain from the UK has doubled since 2009 and is no longer an insignificant minority of horses. All vets should be checking horse passports and only dispensing sensible quantities of this drug, and its prodrug suxibuzone."
Meanwhile, a form is available from the British Equine Veterinary Association website for veterinary surgeons to use if the horse passport is not available, but emergency treatment is required: http://www.beva.org.uk/_uploads/documents/emergency-treatment-form-no-passport-2011.pdf
Eclipse Veterinary Software has released a new mobile addition to its equine veterinary practice management system.
Eclipse Mobile allows veterinary surgeons to access up-to-date clinical information wherever it is needed, be that on the yard, at the practice, or while making field visits.
When Eclipse Mobile is offline, all the information the vet needs is stored on the device. When next connected via 3G or Wi-Fi, any new details are sent to and from the practice - syncing notes made by the vet, adding follow-on appointments and To Do messages, services delivered and products administered to keep everyone up-to-date throughout the day.
Whilst online, client payments can be taken via debit/ credit cards within the app and detailed drug batch information recorded using the iPad/iPhone's camera as a barcode scanner, if required.
Jeanne Razzell, CEO of Eclipse said: "Many of the vets we work with have been keen to carry animal histories with them on visits, including the latest lab test results, together with recent clinical notes, and diagnostic imaging, e.g. x-rays, ultrasounds and MRI, CT or bone scans. Now, with Eclipse Mobile, every vet can have all of this information at their fingertips automatically - at every appointment; both in the consult room and on the road."
Eclipse Mobile is available for iPad, iPad mini, iPhone, Android smart phones/tablets and Microsoft Windows Surface
For more information, contact Jeanne Razzell, CEO, Eclipse Veterinary Software Limited, on +44 (0)1799 532988 or +44 (0)7515 906466. Website: www.eclipsesoftware.info
New research from the USA, published in the Equine Veterinary Journal (EVJ), has shown that a toxin from the box elder tree is the likely cause of Seasonal Pasture Myopathy (SPM), the US equivalent of the European disease known as Atypical Myopathy (AM).
According to the British Equine Veterinary Association, preliminary comparisons of these results with cases of AM in Europe suggest that the European condition may be linked to similar trees which could have an important bearing on the future prevention of the disease in Europe.
Seasonal Pasture Myopathy is a highly fatal muscle disease in Midwestern USA and Eastern Canada. A similar disorder called Atypical Myopathy is becoming increasingly frequent in the UK and Northern Europe. Outbreaks of both diseases tend to be seasonal, with most cases occurring in the autumn. Horses that develop SPM and AM are usually kept in sparse pastures with an accumulation of dead leaves dead wood and trees in or around the pasture and are often not fed any supplementary hay or feed.
The research1 identified that seeds from box elder trees were consistently present in the autumn pastures of all 12 horses enrolled in the study. These horses were from 11 different farms and had all presented with the clinical signs of SPM, which include muscular weakness and stiffness, dark urine, periods of recumbency, colic-like signs and muscle trembling. The toxic amino acid hypoglycin A, which is known to cause acquired multiple acyl CoA dehydrogenase deficiency (MADD) was shown to be present in the box elder seeds and hypoglycin metabolites were identified in the serum or urine of all the horses. All but one of the cases proved fatal.
Professor Valberg DVM PhD of the Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, who instigated the study, said: "The fact that another acquired form of MADD in rats and humans is caused by hypoglycin A ingestion strengthens our conclusion that hypoglycin A is the likely toxic cause of SPM in horses. We are intending to conduct further studies to determine the factors that affect the highly variable hypoglycin A concentrations in box elder seeds."
Professor Valberg has established collaborative links with groups in Europe in order to investigate if a similar toxin is involved in European Atypical Myopathy. Working with Professor Vince Gerber and Dr Lucia Unger at the University of Bern, Professor Valberg has obtained seeds from a tree related to the Box Elder found on many pastures where Atypical Myopathy has occurred.
Professor Celia Marr, Editor of Equine Veterinary Journal said: "This is a really important step forwards. We don't yet know for sure that the cause of European disease, Atypical Myopathy, is the same as Seasonal Pasture Myopathy in the US. But the clinical signs and MADD aberrations are identical and both conditions have a high fatality rate. It remains to be seen whether this research will help European horses, but there is no doubt that it will allow American horse owners to prevent this devastating condition affecting their horses with immediate effect."
1 Seasonal Pasture Myopathy/Atypical Myopathy in North America associated with Ingestion of Hypoglycin A within Seeds of the Box Elder Tree Stephanie J Valberg DVM PhD1, Beatrice T Sponseller Dr. med. vet2, Adrian D Hegeman PhD3, Jennifer Earing PhD, Jeffery B. Bender DVM MS1, Krishona L Martinson PhD4, Steven E Patterson PhD5, Lawrence Sweetman PhD1
The British Equine Veterinary Association (BEVA) and the British Association of Equine Dental Technicians (BAEDT) have joined forces to set recognised standards for equine dental treatment.
The two organisations are working in association with the RCVS, BVA, BVDA, WWAED and LANTRA to develop National Occupational Standards that will pave the way to allowing equine dental technicians the freedom to work within the Law under an Exemption Order. This should make it safer and easier for owners to source the most suitable dental treatment for their horses.
Currently all equine dental care falls within the Veterinary Surgeons Act 1966 (VSA) and should only be carried out by veterinary surgeons. Equine vets from BEVA and equine dental technicians from the BAEDT have been trying to address this anomaly with government for many years. In 2004 the organisations drew up a list (revised in 2009) of procedures that could be safely carried out by suitably qualified equine dental technicians and a list of those which should only be carried out by qualified veterinary surgeons because they involve sensitive tissues.
The envisaged Exemption Order will also provide better protection for horses and their owners by reinforcing the fact that only suitably qualified individuals are allowed to carry out equine dental care and treatments. While unqualified individuals should become easier to identify under the proposed new scheme, those qualified will also be held to account if their performance is not up to scratch.
The first step towards the Exemption Order is the drawing up of National Occupational Standards for Equine Dental Technicians. It is hoped that these will be formalised by LANTRA in early 2013.
Keith Chandler, BEVA President said: "After many years of working closely with the BAEDT on the continuing education and qualification of its members, we are thrilled that progress is finally being made towards an Exemption Order."
BAEDT Chair, Gemma Lilly, said: "BAEDT and its membership is very happy to be a key part of the team that hopes to put the Exemption Order in place - it will be good news for equine dental technicians, horse owners, and their animals."
Equine Dental Technician and member of the Worldwide Association of Equine Dentists, Martin Brookes, also supports the initiative. He said: "This will be a really important step forward for responsible Equine Dental Technicians. It will further improve the working relationships between EDTs and vets and help to protect the welfare of the horse."
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
BCF Technology has announced the launch of the Logiq S7 Expert ultrasound system.
BCF says the new system offers the latest in ultrasound technology and represents a significant leap forward in imaging capability.
The Logiq S7 ultrasound system includes features such as B-Flow, Elastography, Flow Quantification, Contrast Imaging, B-Steer+, 3D/4D ultrasound, Volume Imaging and Multi-Modality Imaging Display.
Nigel Perry from BCF said: "The new Logiq S7 Expert provides the highest image quality currently available in the market. With a wide range of probes available for every veterinary application. If you are looking for the ultimate in ultrasound capability then the Logiq S7 is the system for you."
For more information, visit http://www.bcftechnology.co.uk/ or call +44(0)1506 460 023.
The Animal Health Trust has presented the results of a study which has identified a significant link between hind limb lameness and saddle slip, showing consistent saddle slip in some horses with hind limb lameness, even when the lameness is fairly subtle and difficult to detect.
According to the AHT, saddle slip in sports horses is a well-recognised problem that can occur for a variety of reasons, including asymmetry in the shape of the horse's back, riders sitting crookedly and ill-fitting saddles. Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust, had also observed that saddle slip may occur because of hind limb lameness. The intention of the study, therefore, was to find out more about the interrelationships between the horse, saddle and rider and to document the frequency of occurrence of saddle slip in horses with hind limb lameness compared with other horses.
The research was undertaken by Sue Dyson and Intern Line Greve and was presented at the British Equine Veterinary Association (BEVA) Congress last month. It is thought to be the first study of its kind, and was supported by the Saddle Research Trust (SRT). The SRT is a charitable organisation, aiming to facilitate research and provide support as well as advice on the influence of the saddle on the welfare and performance of horses and riders.
The study assessed 128 horses of varying size, age and type. The degree of lameness of each horse was graded; back shape and symmetry were measured and saddles assessed for symmetry and fit. Each horse was ridden by at least two riders and rider straightness plus weight were recorded. The grade of saddle slip, whether it occurred with more than one rider, and whether saddle slip was influenced by the direction of movement or the diagonal on which the rider was sitting were also noted.
The saddle consistently slipped to one side in 54% of horses with hind limb lameness, compared with 4% of horses with fore limb lameness, 0% with back pain and/or sacroiliac joint region pain and 0% of non-lame horses. Diagnostic analgesia was subsequently used to abolish the hind limb lameness and this eliminated the saddle slip in 97% of cases.
Sue said: "Our findings emphasise the need to educate owners, veterinarians, physiotherapists, trainers, riders and saddle fitters that saddle slip is frequently an indicator of lameness, not necessarily a manifestation of an ill-fitting saddle or asymmetric shape of the horse's back. Detection of saddle slip provides an opportunity for the owner, riders and trainers to detect low-grade and subclinical lameness, with important welfare consequences."
Further scientific studies are planned, with the support of the Saddle Research Trust, in order to build on these findings. To this end the SRT is currently seeking an honorary fundraiser to help secure ongoing financial support. For further information contact Anne Bondi on 07775 912202 or email annebondi@me.com.
1An investigation of the relationship between hindlimb lameness and saddle slip, L. Greve and S.J. Dyson, Centre for Equine Studies, Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, CB8 7UU, UK.
Elanco Companion Animal Health has announced that its Duvaxyn IE and IE-T Plus vaccines have been licensed for active immunisation against OIE recommended clade 1 and clade 2 equine influenza strains, the first vaccines to be so licensed.
The company says the updated license is a result of a recent challenge study which demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to induce cross protection against clade 2 strain A/equi-2/Richmond/1/07 (H3N8) two weeks after two doses of the primary course1 were given. Cross-protection was further supported by another study2 measuring serum antibody response to the Richmond '07 strain 52 weeks after the three dose primary vaccination course.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade3.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health UK, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of our challenge study and subsequent licence update provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE has identified as being of concern.
"Further reassurance is also given with the confirmation in our study that Duvaxyn IE-T Plus elicits a cell mediated immune response, recognised to play an important role to aid in viral clearance and further enhances protection against strains circulating in the field." 4
The live virus challenge study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two doses of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Duvaxyn IE-T Plus is the only inactivated whole virus carbomer adjuvanted equine influenza vaccine in the UK. According to Elanco, experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins including the conserved nucleoprotein, which shows no antigenic drift, in the vaccine5.
Petplan Equine has announced the finalists for the fifth annual Petplan Equine Vet of the Year Award.
The winner of the award award, which is sponsored by Petplan Equine in association with Horse & Rider magazine, will be announced at the annual Animal Health Trust Equestrian Awards, being held at London's Lancaster Hotel on Thursday 1st November, 2012.
The finalists are:
Jess Hill BVM&S MRCVS Woodlands Veterinary Clinic, Cheltenham, Glos, EnglandJess, who qualified in 2003 at the University of Edinburgh Royal (Dick) School for Veterinary Studies, is described as simply "brilliant" for her outstanding calm, capable and kind approach to her work and the way in which she makes herself readily available to her clients. One nomination typifies all those received in praise of Jess' work: "She is incredibly knowledgeable and dedicated and nothing is too much trouble. She is great with horses - always quiet, kind and gentle. She works quickly and confidently, doesn't suggest unnecessary expensive procedures and is always cheerful and a pleasure to be with."
Keith Chandler BVMS Cert EP MRCVS, Kessock Equine Vets, Inverness, ScotlandKeith Chandler, a senior partner at Kessock Equine Vets received several nominations which credited not only him personally for his dedication, knowledge, pragmatic and caring approach but also his practice for its outstanding customer service. Upon receiving news of his nomination, Keith was swift to praise his team and explained: "This nomination reflects the exceptional team I have around me - together we strive to offer continuity, consistency and a minimum level of care to all our clients irrespective of which vet is in attendance."
Lee Paul, BSC BVM&S Cert EP MRCVS, Bushy Equine, Gwaelod-y-Garth, WalesNominations for Lee Paul, a specialist in internal and stud medicine who qualified at Edinburgh University's Royal Dick Veterinary School in 2002, unanimously praised his willingness to 'never give up' and to go beyond the call of duty. He is said to be highly dedicated and is praised for his willingness to always be available such as on the occasion when a horse he had been treating for a swelling in her throat presented complications during a weekend when he was not on duty. Despite this Lee, who had been contacted by the duty vet for background information, attended the call himself within an hour complete with the stethoscope he'd collected from the surgery en route and with his family in his car!
This year's judges were David Stickles, Head of Fund Raising at the Animal Health Trust, Alison Bridge, Editor of Horse & Rider magazine, Ben Mayes, President of the British Equine Veterinary Association (BEVA) and Gil Riley, 2009 Petplan Equine Vet of the Year.
Petplan says that the record number of high calibre nominations made it hard for the judges to choose three finalists. Isabella Von Mesterhazy, Head of Marketing for Petplan Equine said: "Anyone motivated to nominate their vet for this award must hold them in extremely high regard so once again we were very impressed by both the quality and quantity of nominations we received. It is heartwarming and inspiring to read the submissions that describe the outstanding contributions made by all the nominees in keeping owners happy and horses healthy. It has not been easy to select just three to go through to the final."
The winner will be posted on www.petplanequine.co.uk on Friday 2 of November.
Boehringer Ingelheim Vetmedica has released data which shows that one third of laminitic middle aged horses (between the ages of 10 and 15 years) test positive for PPID (Cushing's)1.
Over 3,100 horses were tested for Cushings as part of the company's 'Talk about Laminitis' campaign during the spring.
Liz Barrett, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Although the common perception is that PPID is a disease of only older horses and ponies, the ageing process is progressive and this data from over 330 participating veterinary practices1 indicates that horses and ponies in the 10 to 15 age bracket are also frequently affected."
The company is urging veterinary surgeons to test laminitic or foot-sore horses for PPID this autumn, as this is when there is a greater difference between horses with PPID and those free of the disease2, 3. In support of this, Boehringer will be re-launching its disease awareness initiative 'Talk About Laminitis', with free ACTH blood tests* during September, October and November. To participate in the scheme, veterinary surgeons can download free ACTH blood test vouchers from http://www.talkaboutlaminitis.co.uk/.
Dr Catherine McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS from the University of Liverpool, said: "It is very important to test horses for PPID the first time they present with laminitis because what we want to avoid is recurrence of that laminitis. If it does reoccur, the damage will be worse and the chances of that horse having a successful long-term recovery will be diminished."
For further information on 'Talk About Laminitis', PPID or Prascend, visit www.talkaboutlaminitis.co.uk, contact your Boehringer territory manager or call 01344 746959.
Pfizer Animal Health, maker of the equine wormers Equest & Equest Pramox, has launched Stable Mate, a new app to help horse owners manage their daily equine healthcare regime and get maximum enjoyment from their horse.
Pfizer says the new app has been described by testers as 'undoubtedly the best equestrian electronic management system you could wish for'. It includes an organiser in which to keep horses' records and details of their management requirements. It also includes Track My Ride, a GPS mapping and exercise planning service, and a news feed direct from Horse & Hound.
Stable Mate allows users to keep records for up to six horses on their iPhone. They just need to enter the information needed to keep track of each horse's health routine, including worm control, vaccinations, dentistry, farriery and feeding regime. The app then creates a calendar of events, appointments and reminders designed to make it easy for owners to keep their horse's essential healthcare needs on course.
Records can be passed to a yard manager or friends when the owner goes on holiday, making a temporary transfer of care straightforward. Stable Mate also offers general equine health advice, from the essentials of pasture management to understanding vaccination protocols.
Track My Ride is a GPS navigation system that allows owners to map the route, duration and speed of each ride. Pfizer says it's a great device for planning and monitoring exercise programmes, that owners can use it to explore new hacking routes safely and that they'll never have to worry about finding their way back to their horse box again when hunting or doing a long distance ride. Details of each ride are stored in a history log and can be shared with friends through social media.
Paul Blanc, Pfizer's equine brand manager said: "We have tried to develop an app that is all about the horse and their owner, making it as easy as possible for owners to keep their equine health care on track as well as add to the fun and pleasure with their horse. Stable Mate has well and truly surpassed our expectations. We hope that owners and riders find Stable Mate useful and enjoyable."
Stable Mate is currently available only for iPhone with Android and Blackberry coming soon.
Stable Mate is available free from the iPhone App Store http://itunes.apple.com/us/app/stable-mate/id532341393?ls=1&mt=8. To find out more visit www.wormingyourhorse.info.
Vetoquinol, makers of Sedalin (acepromazine), has published a free clipping guide for horse owners.
The company says the launch of the guide has been timed to coincide with the horse clipping season, when owners may be considering sedating horses to make things safer for themselves and their horses.
The guide refers owners to their veterinary surgeon for professional advice if sedation is appropriate.
The company has also produced promotional practice posters: ' Less Stress more Success'
For your poster and accompanying guides, contact your Vetoquinol Territory Manager or Teleservices directly on 01280 825424. You may also wish to put a link to a downloadable version of the guide on your practice website: http://www.vetoquinol.co.uk/clippingguide.pdf
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
Merial has launched a limited trial pack version of Equioxx® (firocoxib), the company's COX-2 specific NSAID for horses, which contains 10 tubes of the oral paste.
According to the company, Equioxx is the only equine NSAID that is highly COX-2 selective, acting to reduce pain and inflammation whilst preserving the natural physiological effects of the COX-1 enzyme, at therapeutic levels.
The company also claims that field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.
Jim Tipp BVSc MRCVS, partner at Shropshire based Fyrnwy Equine Clinics said: "As a COX-2 specific NSAID it is not only a good analgesic, but is also an excellent anti-inflammatory. In addition, the COX-1 sparing properties of Equioxx are beneficial where there is increased risk of ulceration."
Equioxx is also available as a low dose injectable solution. For more information contact Merial Customer Services on 0870 6000 123.
Vetoquinol has announced the launch of Chrysanphyton, the latest addition to its range of Equistro feeding stuffs for horses.
Vetoquinol says Chrysanphyton is recommended for horses where support of a normal blood flow to the hoof is important. It contains Chrysantellum americanum, blackcurrant and hazelnut extracts which, according to the company, provide a rich source of nutrient bioflavanoids and vitamins.
The recommended administration of Chrysanphyton is 10ml twice a day in horses (500kg) and 5ml twice a day in ponies with the 1000ml pack lasting 50 or 100 days respectively.
A product information sheet is available on the Equistro website www.equistro.co.uk
For further information contact your local Vétoquinol Territory Manager.